Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Leigh Calcote

Nurse Practitioner, Psychiatric/Mental Health Hattiesburg, MS Nurse Practitioner

NPI 1508598376 CMS profile 11362460

1 Lincoln Pkwy Ste 304, Hattiesburg, MS 39402

Open in the dashboard

General payments

$15,079

424 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leigh Calcote of Hattiesburg, MS is reported in the CMS Open Payments database as having received $15,079 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,862 140
2024 General $8,232 168
2023 General $1,652 98
2022 General $332 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leigh Calcote
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Leigh Calcote were reported at $4,862. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Leigh Calcote Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $332 $195 $66–$559 $149
2023 $1,652 $233 $82–$673 $160
2024 $8,232 $236 $84–$688 $164
2025 $4,862 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $8,637 91 payments
  2. ITI, Inc. $1,410 69 payments
  3. Axsome Therapeutics, Inc. $1,013 52 payments
  4. Teva Pharmaceuticals USA, Inc. $606 25 payments
  5. Lundbeck LLC $547 30 payments
  6. Corium, Inc. $485 32 payments
  7. Vanda Pharmaceuticals Inc. $447 25 payments
  8. Otsuka America Pharmaceutical, Inc. $417 19 payments
  9. Supernus Pharmaceuticals, Inc. $341 19 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $331 19 payments
  11. Other $845 43 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,879 418 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,200 6 payments
Products named General payments · program years 2022–2025
  1. VRAYLAR Neuroscience $6,103 67 payments
  2. VRAYLAR Neuroscience $2,533 24 payments
  3. Auvelity $1,013 52 payments
  4. CAPLYTA Psychiatry $921 42 payments
  5. Austedo XR $568 24 payments
  6. CAPLYTA Psychiatry $488 27 payments
  7. Azstarys $485 32 payments
  8. FANAPT $447 25 payments
  9. REXULTI $401 18 payments
  10. Qelbree $341 19 payments
  11. Other $2,144 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

402

Median for Nurse Practitioner: 389

Drug cost

$45,033

Median for Nurse Practitioner: $21,885

Branded share of claims

20.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Caplyta Lumateperone Tosylate Brand 19 $39,462
Oxcarbazepine Generic 21 $1,069
Quetiapine Fumarate Generic 55 $859
Duloxetine Hcl Generic 28 $529
Bupropion Xl Bupropion Hcl Brand 34 $411
Mirtazapine Generic 12 $406
Buspirone Hcl Generic 32 $404
Venlafaxine Hcl Er Venlafaxine Hcl Brand 31 $351
Prazosin Hcl Generic 13 $289
Lamotrigine Generic 48 $286

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $5,758
$5,758 — —
CAPLYTA
  • ITI, Inc. $600
$600 19 —
Auvelity
  • Axsome Therapeutics, Inc. $351
$351 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $179
  • Lundbeck LLC $125
$304 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $255
$255 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record